Targeting cysteine-rich angiogenic inducer-61 by antibody immunotherapy suppresses growth and migration of non-small cell lung cancer.

In conclusion, CYR-61 may serve as a potential target for gene therapy for the treatment of human NSCLC. PMID: 30116327 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research